ABSTRACT
Aurora kinase inhibitors, such as alisertib, can destabilize MYC-family oncoproteins and have demonstrated compelling antitumor efficacy. In this study, we report 6K465, a novel pyrimidine-based Aurora A inhibitor, that reduces levels of c-MYC and N-MYC oncoproteins more potently than alisertib. In an analysis of the antiproliferative effect of 6K465, the sensitivities of small cell lung cancer (SCLC) and breast cancer cell lines to 6K465 were strongly associated with the protein levels of c-MYC and/or N-MYC. We also report DBPR728, an acyl-based prodrug of 6K465 bearing fewer hydrogen-bond donors, that exhibited 10-fold improved oral bioavailability. DBPR728 induced durable tumor regression of c-MYC- and/or N-MYC-overexpressing xenografts including SCLC, triple-negative breast cancer, hepatocellular carcinoma, and medulloblastoma using a 5-on-2-off or once-a-week dosing regimen on a 21-day cycle. A single oral dose of DBPR728 at 300 mg/kg induced c-MYC reduction and cell apoptosis in the tumor xenografts for more than 7 days. The inhibitory effect of DBPR728 at a reduced dosing frequency was attributed to its uniquely high tumor/plasma ratio (3.6-fold within 7 days) and the long tumor half-life of active moiety 6K465. Furthermore, DBPR728 was found to synergize with the mTOR inhibitor everolimus to suppress c-MYC- or N-MYC-driven SCLC. Collectively, these results suggest DBPR728 has the potential to treat cancers overexpressing c-MYC and/or N-MYC.
Subject(s)
Aurora Kinase A , Everolimus , Proto-Oncogene Proteins c-myc , Xenograft Model Antitumor Assays , Humans , Animals , Aurora Kinase A/antagonists & inhibitors , Mice , Proto-Oncogene Proteins c-myc/metabolism , Proto-Oncogene Proteins c-myc/genetics , Everolimus/pharmacology , Everolimus/pharmacokinetics , Everolimus/administration & dosage , Cell Line, Tumor , Female , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/pharmacokinetics , Cell Proliferation/drug effects , Neoplasms/drug therapy , Neoplasms/pathology , Pyrimidines/pharmacology , Pyrimidines/pharmacokinetics , Pyrimidines/administration & dosage , Pyrimidines/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic useABSTRACT
Aim: Cancer is a major health burden and a leading cause of death worldwide. We sought to discover potential anticancer molecules with novel scaffold for further development of more active agents to address the issue. Methodology: A series of ß-carboline-1-one hydantoins were designed according to a conformational restriction strategy, synthesized via a one-pot Knoevenagel condensation-intramolecular cyclization, and tested in cytotoxicity assays. Results: The study culminated in the identification of 6b and 6c, both of which were found to potently inhibit breast and lung cancer cell lines. Of particular interest was 6c, which was 83 times more potent an inhibitor than 5-fluorouracil in inhibiting MCF-7. Conclusion: This work establishes ß-carboline-1-one hydantoin as a promising scaffold in the investigation of anticancer agents.
Subject(s)
Antineoplastic Agents/pharmacology , Carbolines/pharmacology , Drug Design , Hydantoins/pharmacology , A549 Cells , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Carbolines/chemical synthesis , Carbolines/chemistry , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Hydantoins/chemical synthesis , Hydantoins/chemistry , MCF-7 Cells , Molecular Structure , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
Sodium-dependent glucose co-transporter 2 (SGLT2) inhibition has been demonstrated to efficiently control hyperglycemia via an insulin secretion-independent pathway. The unique mode of action eliminates the risk of hypoglycemia and makes SGLT2 inhibitors an attractive option for the treatment of type 2 diabetes. In a continuation of our previous studies on SGLT2 inhibitors bearing different sugar moieties, sixteen new N-glucosyl indole derivatives were designed, synthesized, and evaluated for their inhibitory activity against hSGLT2. Of these sixteen, acethydrazide-containing N-glucosyl indole 9d was found to be the most potent SGLT2 inhibitor, and caused a significant elevation in urine glucose excretion in rats at 50â¯mg/kg, relative to the vehicle control.
Subject(s)
Glucosides/pharmacology , Indoles/pharmacology , Sodium-Glucose Transporter 2 Inhibitors/pharmacology , Sodium-Glucose Transporter 2/metabolism , Animals , Benzhydryl Compounds/pharmacology , CHO Cells , Cricetulus , Glucosides/chemical synthesis , Glucosides/chemistry , Glucosides/pharmacokinetics , Humans , Indoles/chemical synthesis , Indoles/chemistry , Indoles/pharmacokinetics , Molecular Structure , Rats, Sprague-Dawley , Sodium-Glucose Transporter 2 Inhibitors/chemical synthesis , Sodium-Glucose Transporter 2 Inhibitors/chemistry , Sodium-Glucose Transporter 2 Inhibitors/pharmacokinetics , Structure-Activity RelationshipABSTRACT
Treatment of hyperglycemia with drugs that block renal glucose reabsorption via inhibition of sodium-dependent glucose cotransporter 2 (SGLT2) is a novel approach to diabetes management. In this study, twenty-seven aryl C-glycosides bearing a C=N/C-N linkage at the glucosyl C6 position were designed, synthesized and evaluated for their inhibitory activity against human SGLT2 (hSGLT2). Compounds with good hSGLT2 inhibition were further investigated to determine their selectivity over hSGLT1. Of these, five representative aryl C-glycosides were chosen for pharmacokinetic analysis. Oxime 2a was determined to have the most promising pharmacokinetic properties and was selected for in vivo glucosuria and plasma glucose level studies, which found it to exhibit comparable efficacy to dapagliflozin (1). Furthermore, 2a was not found to exhibit either significant cytotoxicity (CC50 > 50 µM) or human ether-a-go-go related gene (hERG) inhibition (2% inhibition at 10 µM). Taken together, these efforts culminated in the discovery of oxime 2a as a potential SGLT2 inhibitor.
Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/pharmacology , Monosaccharides/pharmacology , Oximes/pharmacology , Sodium-Glucose Transporter 2 Inhibitors , Administration, Intravenous , Administration, Oral , Animals , Benzhydryl Compounds/administration & dosage , Benzhydryl Compounds/pharmacology , Blood Glucose/drug effects , Dose-Response Relationship, Drug , Glucose/analysis , Glucosides/administration & dosage , Glucosides/pharmacology , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/chemistry , Molecular Structure , Monosaccharides/chemistry , Oximes/administration & dosage , Oximes/chemistry , Rats , Rats, Sprague-Dawley , Sodium-Glucose Transporter 2 , Structure-Activity RelationshipABSTRACT
Suppression of glucose reabsorption through the inhibition of sodium-dependent glucose co-transporter 2 (SGLT2) is a promising therapeutic approach for the treatment of type 2 diabetes. To investigate the effect of C6-substitution on inhibition of SGLT2 by N-indolylglucosides, a small library of 6-triazole, 6-amide, 6-urea, and 6-thiourea N-indolylglycosides were synthesized and tested. A detailed structure-activity relationship (SAR) study culminated in the identification of 6-amide derivatives 6a and 6o as potent SGLT2 inhibitors, which were further tested for inhibitory activity against SGLT1. The data obtained indicated that 6a and 6o are mildly to moderately selective for SGLT2 over SGLT1. Both compounds were also evaluated in a urinary glucose excretion test and pharmacokinetic study; 6a was found capable of inducing urinary glucose excretion in normal SD rats.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glycosides/chemistry , Glycosides/pharmacology , Sodium-Glucose Transporter 2 Inhibitors , Animals , CHO Cells , Cricetulus , Diabetes Mellitus, Type 2/metabolism , Glucose/metabolism , Glycosides/pharmacokinetics , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacokinetics , Hypoglycemic Agents/pharmacology , Rats, Sprague-Dawley , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacokinetics , Small Molecule Libraries/pharmacology , Sodium-Glucose Transporter 2/metabolismABSTRACT
Motivated by the pivotal role of CXCR4 as an HIV entry co-receptor, we herein report a de novo hit-to-lead effort on the identification of subnanomolar purine-based CXCR4 antagonists against HIV-1 infection. Compound 24, with an EC50 of 0.5 nM against HIV-1 entry into host cells and an IC50 of 16.4 nM for inhibition of radioligand stromal-derived factor-1α (SDF-1α) binding to CXCR4, was also found to be highly selective against closely related chemokine receptors. We rationalized that compound 24 complementarily interacted with the critical CXCR4 residues that are essential for binding to HIV-1 gp120 V3 loop and subsequent viral entry. Compound 24 showed a 130-fold increase in anti-HIV activity compared to that of the marketed CXCR4 antagonist, AMD3100 (Plerixafor), whereas both compounds exhibited similar potency in mobilization of CXCR4(+)/CD34(+) stem cells at a high dose. Our study offers insight into the design of anti-HIV therapeutics devoid of major interference with SDF-1α function.
Subject(s)
CCR5 Receptor Antagonists/pharmacology , HIV Fusion Inhibitors/pharmacology , HIV Infections/drug therapy , HIV-1/drug effects , Receptors, CXCR4/antagonists & inhibitors , Virus Internalization/drug effects , Animals , CCR5 Receptor Antagonists/chemical synthesis , CCR5 Receptor Antagonists/chemistry , Cell Line , Dose-Response Relationship, Drug , HIV Fusion Inhibitors/chemical synthesis , HIV Fusion Inhibitors/chemistry , HIV Infections/virology , HIV-1/metabolism , Humans , Male , Mice , Mice, Inbred C57BL , Microbial Sensitivity Tests , Molecular Dynamics Simulation , Molecular Structure , Receptors, CXCR4/metabolism , Structure-Activity RelationshipABSTRACT
The freshwater golden apple snail, Pomacea canaliculata, is one of the world's 100 worst invasive alien species. The snails' wide distribution, high abundance, and sensitivity to environmental pollution make them a potential bioindicator for environmental contamination. In this study, the biochemical status of golden apple snails collected from paddy fields throughout the island of Taiwan was examined. This study found that the biochemical status of apple snails collected from paddy fields differed from that of animals bred and maintained in the laboratory. Furthermore, certain biochemical endpoints of the snails collected from the paddy fields before and after agricultural activities were also different-hemolymphatic vitellogenin protein was induced in male snail after exposure to estrogen-like chemicals, the hepatic monooxygenase (1.97 +/- 0.50 deltaA(650mm) 30 min(-1) mg(-1) protein in control group) and glutathione S transferase (0.02 +/- 0.01 delta A(340mm) 30 min(-1) mg(-1) protein in control group) snails exposed to pesticides, as well as the hepatopancreatic levels of aspartate aminotransferase (450.00 +/- 59.40 U mg(-1) mg(-1) protein in control group) and alanine aminotransferase (233.27 +/- 42.09 U mg(-1) mg(-1) protein in control group) decreased the indicating that xenobiotics destroyed hepatopancreatic. The above findings reveal that apple snail could be used as a practical bioindicator to monitor anthropogenic environmental pollution.
Subject(s)
Environmental Monitoring/methods , Hepatopancreas/metabolism , Snails/drug effects , Water Pollutants, Chemical/metabolism , Agriculture , Animals , Biomarkers/blood , Biomarkers/metabolism , Creatinine/metabolism , Hepatopancreas/enzymology , Introduced Species , Oryza/growth & development , Snails/enzymology , Snails/metabolism , Urea/metabolism , Vitellogenins/bloodABSTRACT
Novel C-aryl-d-glucofuranosides were synthesized and evaluated for their capacity to inhibit human sodium-dependent glucose co-transporter 2 (hSGLT2) and hSGLT1. Compound 21q demonstrated the best in vitro inhibitory activity against SGLT2 in this series (EC50=0.62µM).
Subject(s)
Benzhydryl Compounds/chemical synthesis , Glucosidases/chemical synthesis , Glucosides/chemistry , Sodium-Glucose Transporter 2 Inhibitors , Animals , Benzhydryl Compounds/chemistry , Benzhydryl Compounds/metabolism , CHO Cells , Cricetinae , Cricetulus , Glucosidases/chemistry , Glucosidases/metabolism , Glucosides/chemical synthesis , Glucosides/metabolism , Humans , Phlorhizin/chemistry , Protein Binding , Sodium-Glucose Transporter 1/antagonists & inhibitors , Sodium-Glucose Transporter 1/genetics , Sodium-Glucose Transporter 1/metabolism , Sodium-Glucose Transporter 2/genetics , Sodium-Glucose Transporter 2/metabolism , Structure-Activity RelationshipABSTRACT
Sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors are the current focus on the indication for the management of hyperglycemia in diabetes. Here, a novel series of C-linked indolylxyloside-based inhibitors of SGLT2 has been discovered. Structure-activity relationship studies revealed that substituents at the 7-position of the indole moiety and a p-cyclopropylphenyl group in the distal position were necessary for optimum inhibitory activity. The pharmacokinetic study demonstrates that the most potent compound 1i is metabolically stable with a low clearance in rats. In further efficacy study, 1i is found to significantly lower blood glucose levels of streptozotocin (STZ)-induced diabetic rats.
Subject(s)
Glycosides/chemical synthesis , Glycosides/pharmacology , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/pharmacology , Sodium-Glucose Transporter 2 Inhibitors , Animals , CHO Cells , Chemistry Techniques, Synthetic , Cricetinae , Cricetulus , Drug Stability , Glycosides/chemistry , Humans , Hypoglycemic Agents/chemistry , Inhibitory Concentration 50 , Male , Rats , Rats, Sprague-Dawley , Sodium-Glucose Transporter 1/antagonists & inhibitorsABSTRACT
Diosgenin (3ß-hydroxy-5-spirostene, 1), a plant-derived sapogenin, is used as a dietary supplement. However, the biological effects of 1 related to viral replication remain unexplored. In this study, the effects of 1 on hepatitis C virus (HCV) replication were evaluated. Based on a reporter-based HCV subgenomic replicon system, 1 was found to inhibit HCV replication at low micromolar concentrations. The EC(50) (concentration at which 50% of HCV replication is inhibited) of 1 was 3.8 µM. No cellular toxicity was observed at this concentration. Diosgenin (1) also significantly reduced the levels of viral RNA and viral proteins as evaluated by quantitative real-time reverse transcriptase PCR and Western blot analysis, respectively. In addition, in an alternative HCV antiviral system more closely aligned to all steps involved in the HCV infection and life cycle, 1 totally abolished HCV replication at 20 µM. Moreover, 1 reduced the phosphorylation of signal transducer and activator of transcription 3. A combination of 1 and interferon-α exerted an additive effect on the resultant anti-HCV activity.
Subject(s)
Antiviral Agents/pharmacology , Diosgenin/pharmacology , Hepacivirus/drug effects , Sapogenins/pharmacology , Antiviral Agents/chemistry , Antiviral Agents/isolation & purification , Dietary Supplements/analysis , Diosgenin/chemistry , Diosgenin/isolation & purification , Hepacivirus/genetics , Humans , Molecular Structure , RNA, Viral/analysis , RNA, Viral/drug effects , Sapogenins/chemistry , Sapogenins/isolation & purification , Viral Nonstructural Proteins/drug effectsABSTRACT
A novel series of N-linked ß-D-xylosides were synthesized and evaluated for inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) in a cell-based assay. Of these, the 4-chloro-3-(4-cyclopropylbenzyl)-1-(ß-D-xylopyranosyl)-1H-indole 19m was found to be the most potent inhibitor, with an EC(50) value similar to that of the natural SGLT2 inhibitor phlorizin. Further studies in Sprague-Dawley (SD) rats indicated that 19m significantly increased urine glucose excretion in a dose-dependent manner with oral administration. The antihyperglycemic effect of 19m was also observed in streptozotocin (STZ) induced diabetic SD rats. These results described here are a good starting point for further investigations into N-glycoside SGLT2 inhibitors.